Individual Study / ELGAN

ELGAN (Extremely Low Gestational Age Newborns)

ELGAN (Extremely Low Gestational Age Newborns)

ELGAN logo
Initiatives -
To evaluate the relationship between perinatal inflammation and neurodevelopmental impairments among individuals born extremely premature (i.e., before 28 weeks of gestation). In the proposed project we will build on the success of the ELGAN Study by adding new information about: 1. environment exposures 2. neurodevelopmental outcomes of study participants at 15 and 18 years of age 3. placental epigenetic variation, a mechanism that could link inflammation early in life to neurodevelopmental impairments. 
Start Year
2002
Funding
National Institutes of Health (NIH)
Visit ELGAN

Members

Download
Investigators Contacts
  • MD. Prof. Michael O'shea
    School of Medicine - University of North Carolina

Design

Study design
Population cohort
Follow Up
ELGAN researchers have followed over one thousand children born at least 3 months early between 2002 and 2004 at 14 different hospitals in five states. We assessed these premature babies at birth and again when they were two and ten years old. In the first few weeks after birth, when the babies had routine blood tests, we saved a drop or two for later testing. Through analyzing these saved blood samples, we learned that children who had signs of sustained inflammation in their blood were more likely to have development problems when they were 2 and 10 years old.

Recruitment

Sources of Recruitment
  • Families

Number of participants

Number of participants
1,000
Number of participants with biosamples
Supplementary Information
Children born at 14 different hospitals in five states.

Access

Availability of data and biosamples

Data
Biosamples
Other